Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
At this rate, we're hardly going to be able to call the world's largest generic-drug maker, Teva Pharmaceuticals (Nasdaq: TEVA ) , a generic-drug maker at all. In the fourth quarter, branded products at Teva made up 40% of sales, up from 30% in the year-ago quarter.
The additional branded products came from its acquisition of Cephalon last year, but Teva's legacy branded drugs also contributed to the 27% increase in branded sales. Multiple sclerosis drug Copaxone jumped 11%, and respiratory drugs ProAir and Qvar were up 26% and 27%, respectively.
Generics weren't exactly lagging, up 12% in the fourth quarter. The only weak spot was the U.S., where sales fell 5% despite launches of a generic version of Eli Lilly's (NYSE: LLY ) Zyprexa and an agreement with Ranbaxy to launch its generic version of Pfizer's (NYSE: PFE ) Lipitor. The release of a generic version of Forest Labs' (NYSE: FRX ) Lexapro later this year should help. With the cutthroat market for pricing of U.S. generics, sales growth is very dependent on big launches.
Teva has also made a push into the over-the-counter business. While sales make up only a small portion of total revenue, they grew 19% during the quarter as its joint venture with Procter & Gamble (NYSE: PG ) ramps up.
This diversification was necessary if Teva was going to grow further. It's mastered the generic-drug space's bigger-is-better philosophy, but growth by acquisition can't continue forever. There are only so many generic-drug makers left and only so many new territories to move into.
But don't be lulled into thinking the added branded products make Teva less risky. If anything, I think increasing branded exposure makes the company more risky, considering that they expose the company to patent risk. Yes, Teva already faced that problem with Copaxone, which made up 18% of the company's revenue in 2010. Teva is now less dependent on Copaxone, but it's more dependent in general on branded products and their patents.
For a health-care stock not dependent on products about to face a patent expiration and poised to profit of favorable demographic changes, take a look at what Fool analysts believe is the next rule-breaking multibagger. Get the free report.